Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb:177:106241.
doi: 10.1016/j.rmed.2020.106241. Epub 2020 Dec 3.

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

Marius M Hoeper  1 , Miguel-Angel Gomez Sanchez  2 , Marc Humbert  3 , David Pittrow  4 , Gérald Simonneau  5 , Henning Gall  6 , Ekkehard Grünig  7 , Hans Klose  8 , Michael Halank  9 , David Langleben  10 , Repke J Snijder  11 , Pilar Escribano Subias  12 , Lisa M Mielniczuk  13 , Tobias J Lange  14 , Jean-Luc Vachiéry  15 , Hubert Wirtz  16 , Douglas S Helmersen  17 , Iraklis Tsangaris  18 , Joan A Barberà  19 , Joanna Pepke-Zaba  20 , Anco Boonstra  21 , Stephan Rosenkranz  22 , Silvia Ulrich  23 , Regina Steringer-Mascherbauer  24 , Marion Delcroix  25 , Pavel Jansa  26 , Iveta Šimková  27 , George Giannakoulas  28 , Jens Klotsche  29 , Evgenia Williams  30 , Christian Meier  30 , Hossein-Ardeschir Ghofrani  6 ; Collaborators list
Collaborators, Affiliations
Free article

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

Marius M Hoeper et al. Respir Med. 2021 Feb.
Free article

Abstract

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice.

Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits (usually every 3-6 months) and collated via case report forms.

Results: In total, 326 patients with PAH were included in the analysis. The most common AEs in these patients were dizziness (11.7%), right ventricular (RV)/cardiac failure (10.7%), edema/peripheral edema (10.7%), diarrhea (8.6%), dyspnea (8.0%), and cough (7.7%). The most common SAEs were RV/cardiac failure (10.1%), pneumonia (6.1%), dyspnea (4.0%), and syncope (3.4%). The exposure-adjusted rate of hemoptysis/pulmonary hemorrhage was 2.5 events per 100 patient-years.

Conclusion: Final data from EXPERT show that in patients with PAH, the safety of riociguat in clinical practice was consistent with clinical trials, with no new safety concerns identified and a lower exposure-adjusted rate of hemoptysis/pulmonary hemorrhage than in the long-term extension of the Phase 3 trial in PAH.

Keywords: Clinical practice; Pulmonary arterial hypertension; Pulmonary hypertension; Registry; Riociguat; Safety.

PubMed Disclaimer